Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avidity Biosciences, Inc. - Common Stock (NQ:RNA)

72.08 -0.26 (-0.36%)
Streaming Delayed Price Updated: 11:18 AM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avidity Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Avidity Biosciences (NASDAQ: RNA) Posts Positive Phase 1/2 MARINA Data on AOC 1001, Announcing the First Successful Delivery of RNA to Muscle
Avidity Biosciences, Inc. (NASDAQ: RNA) is engaged as a biopharmaceutical company, which is focused on developing a new class of 
Via Spotlight Growth
News headline image
How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere ↗
The company tested its efforts in myotonic dystrophy 1, a form of muscular dystrophy. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial ↗
 
Via Benzinga
News headline image
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Recap: Avidity Biosciences Q2 Earnings ↗
  Avidity Biosciences (NASDAQ:RNA) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Avidity Biosciences ↗
Avidity Biosciences (NASDAQ:RNA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
What's Going On With Avidity Biosciences Stock? ↗
Avidity Biosciences Inc (NASDAQ: RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the first-ever successful 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AiViva's Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs ↗
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.  
Via Benzinga
News headline image
Short Interest Sector Focus: Healthcare Sector ↗
As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
News headline image
Nasdaq Turns Higher; Crude Oil Rises Over 2% ↗
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. 
Via Benzinga
News headline image
Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories" ↗
 
Via Benzinga
News headline image
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
US Stocks Turn Lower; Dow Dips 175 Points ↗
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday. 
Via Benzinga
News headline image
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
US Stocks Open Higher; Dow Surges 300 Points ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Tuesday. 
Via Benzinga
News headline image
Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study ↗
The stock has a high IBD Digital rating, but plummeted on the news. 
Via Investor's Business Daily
News headline image
FDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trial ↗
The FDA has placed a partial clinical hold on new participant enrollment in Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. 
Via Benzinga
News headline image
Short Interest Sector Focus: Healthcare Sector ↗
As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
News headline image
7 Unknown Biotech Stocks That Could Rocket in 2023 ↗
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
News headline image
Short Interest Sector Focus: Healthcare Sector ↗
As of the close of business on Monday, 8/29, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
News headline image
Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 21.7% to $2.3 during Monday's after-market session. The market value of their outstanding shares is at $68.8 million. 
Via Benzinga
News headline image
Avidity Biosciences Earnings Perspective: Return On Capital Employed ↗
According to data from Benzinga Pro, during Q1, Avidity Biosciences's (NASDAQ:RNA) reported sales totaled $1.79 million. Despite a 11.17% increase in earnings, the company posted a loss of $34.23... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.